New hope for rare blood disorder: daratumumab under study
NCT ID NCT07513948
First seen Apr 14, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This study looks at how well the drug daratumumab works for people with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) when standard treatments fail. Researchers will track 40 patients to see if the drug helps restore normal blood enzyme activity without needing other immune-suppressing medicines. The goal is to gather more evidence on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
RECRUITINGMilan, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.